False claims by any other name: Medtronic and Omnicare cases illustrate the interplay between the False Claims Act and other federal laws regulating commerce with Medicare and Medicaid

by Saul Ewing Arnstein & Lehr LLP

In Brief

  • Government allegations of Medtronic’s alleged incentives to physicians for prescribing its medical devices lead company, while denying wrongdoing, to settle False Claims Act suit predicated on Anti-Kickback Statute.
  • Omnicare, meanwhile, faces a potential appeal to the Supreme Court in a False Claims Act suit premised on the Food, Drug, and Cosmetic Act.

Medtronic, Inc. has agreed to pay $9.9 million to the U.S. government to bring a False Claims Act (“FCA”) suit focused on eight years’ worth of alleged illegal kickbacks to a close, and Omnicare, Inc. awaits the Supreme Court’s decision on a petition for certiorari in a whistleblower case with the potential to render goods or services that violate regulations “false or misleading” under the FCA when paid for by the federal government.


In its civil suit against Medtronic, United States ex rel. Schroeder v. Medtronic, Inc., No. 2:09-cv-0279 WBS EJB (E.D. Cal.), the government alleged that Medtronic influenced physicians to prescribe its brand of pacemakers and implantable defibrillators by paying physicians to speak at events in exchange for their referral business, by providing implanting physicians with free marketing plans and gifts including wine and alcohol, trips to strip clubs, and sporting event tickets. These pacemakers and defibrillators were then billed to Medicare and Medicaid. The suit describes a plan to instruct sales representatives to “review patient charts in friendly doctor’s offices” and to suggest which patients should receive an implant. The lawsuit further alleged that physicians were influenced to implant devices into patients whose mild heart conditions did not warrant such procedures under applicable Food and Drug Administration (“FDA”) criteria.

The Department of Justice press release quotes Assistant Attorney General Stuart F. Delery of the Justice Department’s Civil Division, saying, “This case demonstrates the Department of Justice’s commitment to pursue medical device manufacturers that use improper financial relationships to influence physician decision-making.”

While paying out a hefty sum under the terms of the settlement agreement, Medtronic expressly denies any wrongdoing. The lawsuit itself originated with a complaint filed under the qui tam provisions of the FCA by whistleblower Adolfo Schroeder, a former Medtronic employee. Approximately $1.73 million will flow to Schroeder as a result of the settlement. The Department of Justice Civil Division, the U.S. Attorney’s Office for the Eastern District of California, and the Office of Inspector General of the U.S. Department of Health and Human Services all collaborated on the settlement.

This case highlights the civil ramifications of the Anti-Kickback Statute (“AKS”), which itself is a criminal statute.  In 2010, the FCA, 31 U.S.C. §§ 3729-33, was amended to make clear that claims submitted to the government in violation of the Anti-Kickback Statute, 42 U.S.C. 1320a-7b(b), automatically constitute violations of the FCA. The AKS makes criminal the offer (and receipt) of remuneration in exchange for referring patients to receive certain government-funded services. Thus, any allegation of kickbacks may lead to criminal and civil action.

In Schroeder, the allegation of kickbacks was sufficient to permit the government to proceed under the FCA without the need to plead a false or misleading statement regarding goods or services provided. Non-kickback cases with no showing of fraud do not fare as well – though one case pending before the Supreme Court seeks to challenge that. 


In February 2014, we brought you the story of a whistleblower who appealed the dismissal of his suit to the U.S. Circuit Court of Appeals for the Fourth Circuit, which affirmed the dismissal, in U.S. ex rel Rostholder v. Omnicare, Inc., 745 F.3d 694 (4th Cir. 2014). There, qui tam relator Barry Rostholder had alleged that products sold by Omnicare and reimbursed by Medicare and Medicaid violated the FCA because they were “adulterated” within the meaning of the Food, Drug, and Cosmetic Act. The appellate court reasoned that “the submission of a reimbursement request for [an approved] drug cannot constitute a ‘false’ claim under the FCA on the sole basis that the drug has been adulterated as a result of having been processed in violation of FDA safety regulations.” The court had rejected the reasoning that inferior quality in and of itself can be “misleading” under the FCA.

Rostholder seeks to challenge that determination, and filed a petition for certiorari on May 22, 2014. If the Court overturns the decision below, the result could have wide-reaching ramifications. Not only will it open the door nationwide to civil liability under the FCA for sale of goods and services to the government that violate any applicable regulation, but it may incite a wave of qui tam litigation that seeks to test the boundaries of a newly-interpreted FCA.

DISCLAIMER: Because of the generality of this update, the information provided herein may not be applicable in all situations and should not be acted upon without specific legal advice based on particular situations.

© Saul Ewing Arnstein & Lehr LLP | Attorney Advertising

Written by:

Saul Ewing Arnstein & Lehr LLP

Saul Ewing Arnstein & Lehr LLP on:

Readers' Choice 2017
Reporters on Deadline

"My best business intelligence, in one easy email…"

Your first step to building a free, personalized, morning email brief covering pertinent authors and topics on JD Supra:
Sign up using*

Already signed up? Log in here

*By using the service, you signify your acceptance of JD Supra's Privacy Policy.
Custom Email Digest
Privacy Policy (Updated: October 8, 2015):

JD Supra provides users with access to its legal industry publishing services (the "Service") through its website (the "Website") as well as through other sources. Our policies with regard to data collection and use of personal information of users of the Service, regardless of the manner in which users access the Service, and visitors to the Website are set forth in this statement ("Policy"). By using the Service, you signify your acceptance of this Policy.

Information Collection and Use by JD Supra

JD Supra collects users' names, companies, titles, e-mail address and industry. JD Supra also tracks the pages that users visit, logs IP addresses and aggregates non-personally identifiable user data and browser type. This data is gathered using cookies and other technologies.

The information and data collected is used to authenticate users and to send notifications relating to the Service, including email alerts to which users have subscribed; to manage the Service and Website, to improve the Service and to customize the user's experience. This information is also provided to the authors of the content to give them insight into their readership and help them to improve their content, so that it is most useful for our users.

JD Supra does not sell, rent or otherwise provide your details to third parties, other than to the authors of the content on JD Supra.

If you prefer not to enable cookies, you may change your browser settings to disable cookies; however, please note that rejecting cookies while visiting the Website may result in certain parts of the Website not operating correctly or as efficiently as if cookies were allowed.

Email Choice/Opt-out

Users who opt in to receive emails may choose to no longer receive e-mail updates and newsletters by selecting the "opt-out of future email" option in the email they receive from JD Supra or in their JD Supra account management screen.


JD Supra takes reasonable precautions to insure that user information is kept private. We restrict access to user information to those individuals who reasonably need access to perform their job functions, such as our third party email service, customer service personnel and technical staff. However, please note that no method of transmitting or storing data is completely secure and we cannot guarantee the security of user information. Unauthorized entry or use, hardware or software failure, and other factors may compromise the security of user information at any time.

If you have reason to believe that your interaction with us is no longer secure, you must immediately notify us of the problem by contacting us at info@jdsupra.com. In the unlikely event that we believe that the security of your user information in our possession or control may have been compromised, we may seek to notify you of that development and, if so, will endeavor to do so as promptly as practicable under the circumstances.

Sharing and Disclosure of Information JD Supra Collects

Except as otherwise described in this privacy statement, JD Supra will not disclose personal information to any third party unless we believe that disclosure is necessary to: (1) comply with applicable laws; (2) respond to governmental inquiries or requests; (3) comply with valid legal process; (4) protect the rights, privacy, safety or property of JD Supra, users of the Service, Website visitors or the public; (5) permit us to pursue available remedies or limit the damages that we may sustain; and (6) enforce our Terms & Conditions of Use.

In the event there is a change in the corporate structure of JD Supra such as, but not limited to, merger, consolidation, sale, liquidation or transfer of substantial assets, JD Supra may, in its sole discretion, transfer, sell or assign information collected on and through the Service to one or more affiliated or unaffiliated third parties.

Links to Other Websites

This Website and the Service may contain links to other websites. The operator of such other websites may collect information about you, including through cookies or other technologies. If you are using the Service through the Website and link to another site, you will leave the Website and this Policy will not apply to your use of and activity on those other sites. We encourage you to read the legal notices posted on those sites, including their privacy policies. We shall have no responsibility or liability for your visitation to, and the data collection and use practices of, such other sites. This Policy applies solely to the information collected in connection with your use of this Website and does not apply to any practices conducted offline or in connection with any other websites.

Changes in Our Privacy Policy

We reserve the right to change this Policy at any time. Please refer to the date at the top of this page to determine when this Policy was last revised. Any changes to our privacy policy will become effective upon posting of the revised policy on the Website. By continuing to use the Service or Website following such changes, you will be deemed to have agreed to such changes. If you do not agree with the terms of this Policy, as it may be amended from time to time, in whole or part, please do not continue using the Service or the Website.

Contacting JD Supra

If you have any questions about this privacy statement, the practices of this site, your dealings with this Web site, or if you would like to change any of the information you have provided to us, please contact us at: info@jdsupra.com.

- hide
*With LinkedIn, you don't need to create a separate login to manage your free JD Supra account, and we can make suggestions based on your needs and interests. We will not post anything on LinkedIn in your name. Or, sign up using your email address.